Keratoconjunctivitis Sicca Clinical Trial
Official title:
Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points
To evaluate tear film stability of a market lubricant therapeutic eye drop versus saline when using Evaporometry and Interferometry in patients with a diagnosis of Keratoconjunctivitis Sicca (KCS). The purpose of this research is to evaluate evaporative parameters and tear film quality when using Systane lubricating eye drops versus saline in the eyes of dry eye patients at pre-instillation and at 30 and 60 minutes post instillation of drop(s).
The goal of this research is to evaluate and compare the effectiveness of Systane® versus
saline on aqueous tear film stability in patients with a diagnosis of Dry Eye Syndrome and
to determine the possible application for this product in the future. Systane® is marketed
as over-the-counter tear lubricating therapy in the United States under the FDA monograph.
Twelve (12) patients will be enrolled in this two-period crossover, randomized study design.
During the course of the study, each patient will be treated with each test articles in the
clinic at separate visits. Following the informed consent procedure, a general ocular
evaluation, including corneal and conjunctival staining, Schirmer testing, evaporometry, and
interferometry assessments will be completed to determine baseline tear evaporation rate.
This will occur before any test article is administered to the patient.
Qualified patients will be randomized into two treatment groups. After 1 hour, in order to
eliminate any residual sodium fluorescein, patients will be administered one drop of
Systane® (40 µl) or saline (40 µl) in each eye per randomization assignment. At 30 and 60
minutes following instillation of drop, evaporometry and interferometry measurements will be
repeated again. These tests (pre and post instillation of drops) will be performed in order
to establish a comparison for later analysis. The estimated time in completing these visits
will be 180 minutes per visit. Patients will be asked to return to the clinic after 2 - 14
days for evaluation of the 2nd assigned treatment.
During the interim study periods, patients will be asked to continue their pre-study
routine; using their pre-study ocular lubricant or other tear products at the same
frequency. Any changes in the frequency of product use during the interim period or any
changes in other concomitant medications will be carefully recorded. This is especially
important since many prescription products (e.g., Claritan) have significant effects on
lacrimal gland physiology.
An effort will be made to schedule all study visits at approximately the same time of day in
order to reduce diurnal variability. For the similar reasons, all patients will be asked not
to use any lubricants or ocular medications within one hour of their office visits.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT02254265 -
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
|
Phase 2/Phase 3 | |
Completed |
NCT00883649 -
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
|
N/A | |
Completed |
NCT00717418 -
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
|
N/A | |
Completed |
NCT00128245 -
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
|
Phase 2 | |
Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
Completed |
NCT04147650 -
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT01733992 -
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT00987727 -
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
|
Phase 4 | |
Completed |
NCT00788229 -
Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00554879 -
Acupuncture Treatment of Dry Eye
|
N/A | |
Completed |
NCT00407043 -
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
|
Phase 4 | |
Completed |
NCT00001731 -
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
|
Phase 2 | |
Recruiting |
NCT03953703 -
Levocarnitine for Dry Eye in Sjogren's Syndrome
|
Phase 2 | |
Withdrawn |
NCT03398018 -
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
|
Phase 4 | |
Recruiting |
NCT02066896 -
Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
|
Phase 3 | |
Completed |
NCT02139033 -
A Phase 4 Study Investigating the Efficacy of Retaineā¢ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
|
Phase 4 | |
Terminated |
NCT01213342 -
Omega-3 Fatty Acid Supplements and Dry Eye
|
N/A | |
Completed |
NCT00201981 -
Study of Rebamipide Eye Drops to Treat Dry Eye
|
Phase 3 | |
Completed |
NCT00201955 -
Study of Rebamipide Eye Drops to Treat Dry Eye
|
Phase 3 |